AZT group

History

2023

Geropharm bought 49% of AZT Group

In early December 2023, it became known about the sale of 49% of the AZT group to the Russian insulin manufacturer Geropharm. Its participants did not disclose the financial and other parameters of the transaction.

According to Vedomosti, citing data from the SPARK-Interfax system, Geropharm bought a stake in AZT on December 5, 2023. Previously, 60% of AZT belonged to Bogdan Brovchenko, and 40% - to the owner of the pharmaceutical company Cosmopharm Igor Varlamov. After the deal with Geropharm, Varlamov left the capital, Brovchenko reduced his share to 51%, the newspaper said.

it became known about the sale of 49% of the AZT group to the Russian insulin manufacturer Geropharm

The representative of Geropharm told Vedomosti that the deal "is due to the importance of combining competencies to ensure the medicinal sovereignty of the country." According to him, the parties will produce socially significant drugs for which "there is an unmet medical need." As a result, the production of drugs, including orphan (rare) drugs, will be established in Russia on the principle of a full cycle, a company representative said.

According to Nikolai Bespalov, RNC Pharma Development Director, 49% in the group that produces full-cycle drugs could cost 200-450 million rubles. The surveyed experts explain the acquisition of the share by the desire to increase the portfolio of their drugs. Now Heropharm does not have orphan drugs, as there are no funds for HIV, said Sergey Shulyak, CEO of DSM Group. Also, cooperation with AZT and full-cycle production, starting with the substance, will allow Geropharm to have advantages when participating in public procurement ("second extra").

Geropharm specializes in the production of insulins - both genetically engineered human and analog. The company's portfolio also includes drugs for the treatment of diseases in the fields of neuropsychiatrics, ophthalmology, endocrinology and gynecology.^[1]

Start production of the component for toothpastes and cosmetics

Moscow "AZT Group" has created a chemical synthesis technology and began to produce calcium glycerophosphate - a component of drugs, vitamins, tonic agents and cosmetological drugs. This was announced at the end of June 2023 by the press service of the Moscow government.

The "AZT group" began to produce calcium glycerophosphate, which is used in cosmetology, added to tonic agents and drugs. In addition, the component is a source of calcium and helps maintain oral hygiene. Toothpastes based on this component have already been proven to effectively remove plaque and prevent the development of tooth decay. Thus, calcium glycerophosphate is included in the unique Mineralin complex patented by Russian developers, which contributes to effective protection against tooth decay, cleavage of plaque and prevents the fixation of bacteria on the teeth and oral mucosa, the developers note.

Moscow company launched the production of a component for toothpastes and cosmetics

By the end of June 2023, AZT Group also continues to work on further optimizing the process of obtaining this component. It is worth noting that the production uses mainly domestic raw materials, reagents and equipment (95%). The planned capacity is designed for 10-15 tons of the component per year. If necessary, the power can be increased.

AZT Group specializes in the production of pharmaceutical products and the synthesis of chemicals, including for the production of drugs. The company received a subsidy to compensate for the cost of purchasing equipment. The volume of investments in the development and production of calcium glycerophosphate in the "AZT Group" by the end of June 2023 is not called.^[2]

Notes